top of page

The Latest In CBD Oil Research Looks Promising

By Laura Kuhl

CBD oil is a market that expected to exceed $2 billion this year. With cannabis legalization sweeping the globe, cannabis companies now jump at new opportunities to research and study the possible medical effects CBD oil has on the human body. Here is the latest coming down the CBD oil research pipeline.

GW Pharmaceuticals Is Right Back At It Again

Even before their first CBD-based medicine earned its coveted FDA approval, GW Pharmaceuticals(NASDAQ:GWPH) was already preparing for the next round. Last December, GW reacquired their rights to Sativex, a cannabis drug for muscle spasticity brought on by Multiple Sclerosis (MS).

Muscle spasticity is a unique symptom of MS. Due to the disease’s inflammation of the nerves in the spinal cord, many patients experience stiffness or numbness in their legs. Studies have shownthat CBD oil directly reduces the inflammation caused by the disease and can even protect the nerves against long-term damage. CBD-based medicines offer up a complementary treatment that can be combined with existing medications and physical therapy.

Because spastic symptoms are unpredictable, GW Pharmaceuticals created Sativex as an oral spray for a quick and easy application. Patients can use Sativex when symptoms hit to reduce discomfort or use the spray every day to slow symptoms. Sativex is readily available to patients in 29 countries but still needs to clear Phase 3 of testing before GW Pharmaceuticals can submit the drug for approval in the United States.

CannTrust Aims To Conquer ALS

Last week CannTrust Holdings Inc. (TSX:TRST) announced a laboratory partnership with Australia’s Gold Coast University Hospital. Together they will conduct a study to determine if CBD oil capsules are capable of slowing the progression of Amyotrophic Lateral Sclerosis (ALS).

ALS is a specific form of scoliosis, characterized by the lateral area of a patient’s spinal cord where the degeneration and inflammation are occurring. Since there is no known cure for the disease, this particular CBD research is aimed at better understanding the disease and slowing its progression. Dr. Sabet, a senior specialist with the hospital, clarified by saying, “This study will help advance our understanding of the potential effects of CannTrust's standardized CBD oil capsules on ALS/MND, both as a disease-modifying agent and as a symptomatic treatment and will become the basis for conducting future cannabinoid and ALS clinical trials.”

Dr. Sabet will be leading the six-month study, investigating the effects of CannTrust’s low-dose CBD capsules on ALS’ unique and varying symptoms.